Comparative Pharmacology
Head-to-head clinical analysis: ALFUZOSIN HYDROCHLORIDE versus HYTRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALFUZOSIN HYDROCHLORIDE versus HYTRIN.
ALFUZOSIN HYDROCHLORIDE vs HYTRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective antagonist of postsynaptic alpha-1 adrenergic receptors in the prostate, bladder base, and prostatic urethra, leading to smooth muscle relaxation and improved urine flow.
Selective alpha-1 adrenergic receptor antagonist; inhibits activation of postsynaptic alpha-1 receptors, resulting in relaxation of smooth muscle in the prostate and bladder neck, improving urinary flow and reducing symptoms of benign prostatic hyperplasia (BPH).
10 mg orally once daily immediately after the same meal each day. Extended-release tablet.
Initial: 1 mg orally once daily at bedtime, increase gradually up to 20 mg/day; typical maintenance: 2-10 mg once daily. For BPH: 5-10 mg once daily. For hypertension: 1-5 mg once daily. Maximum: 20 mg/day.
None Documented
None Documented
Terminal elimination half-life: 5-7 hours in patients with benign prostatic hyperplasia; 7-10 hours in elderly; prolonged in hepatic impairment.
Terminal elimination half-life: 12–13 hours (range 10–15 h); clinical context: steady state achieved in 2–3 days; dose adjustment not required in renal impairment but caution in hepatic impairment.
Primarily hepatic metabolism (CYP3A4); 11% renal excretion as unchanged drug; 69% fecal elimination (biliary), 24% urinary (total).
Renal: ~40% as metabolites, <1% unchanged; biliary/fecal: ~60% as metabolites; total clearance 6.4 L/h.
Category C
Category C
Alpha-1 Blocker
Alpha-1 Blocker